VT
Vitrolife AB (publ)
VTRLY · OTC
$9.50 +0.00% (+$0.00)
Market Cap 12.7B kr
P/E Ratio -
Div. Yield 1.24%
ROE 53.34%
Bulios Fair Price
$8.24
13.3% downside
Current Price
$9.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VTRLY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
69 /100
Cheap P/S 3.75x
P/B 1.56x
P/FCF 20.91x
Growth
15 /100
Declining Rev. growth 2.08%
FCF growth 14.50%
Book val. growth 22.16%
Profitability
50 /100
Moderate Gross margin 57.34%
Net margin 147.49%
Op. margin 141.11%
Quality
4 /100
Poor ROIC 45.57%
ROE 53.34%
ROA 44.08%
Debt
69 /100
Low Debt/Equity 0.20x
Current ratio 3.64x
Int. coverage -127.26x
Stability
35 /100
Moderate Beta 1.71x
Rev. volatility 6.66%
EPS volatility 671.56%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VTRLY
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Bronwyn Brophy O'Connor
Employees
1,151
Headquarters
Gothenburg